Kyle Doherty

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

Vicky Makker, MD, discusses the DESTINY-Endometrial01 trial of T-DXd plus rilvegostomig or pembrolizumab in HER2+ pMMR endometrial cancer.

Eflornithine plus lomustine produced superior OS and PFS outcomes vs lomustine in WHO grade 3 IDH-mutated astrocytoma.

The RP2D of regorafenib when given with temozolomide and radiotherapy in patients with MGMT-methylated, IDH wild-type glioblastoma was 120 mg.

A rolling NDA submission for zipalertinib in NSCLC with EGFR exon 20 insertion mutations who received prior chemotherapy has been initiated.

Shubham Pant, MD, MBBS, and Ryan W. Huey, MD, MS, discuss OXPHOS pathway inhibition in pancreatic cancer with lixumistat.

The European Commission has approved subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma.

Benjamin P. Levy, MD, discusses advances with ADCs in lung cancer during the 20th Annual New York Lung Cancers Symposium.

Satri-cel displayed preliminary efficacy when used as adjuvant treatment in patients with pancreatic ductal adenocarcinoma.

The NDA seeking approval of 177Lu-edotreotide for the treatment of patients with GEP-NETs has been accepted by the FDA.

Based on its previously demonstrated activity and tolerability in ES-SCLC, I-DXd will be examined in the phase 3 IDeate-Lung02 trial.

Anito-cel produced high ORR and sCR/CR rates in patients with relapsed/refractory multiple myeloma.

Dong Kim, MD, discusses the role of NALIRIFOX and other frontline chemotherapy regimens in the pancreatic cancer treatment landscape.

Daniel J. George, MD, discusses the role of lutetium Lu 177 vipivotide tetraxetan in metastatic CRPC and patient selection considerations.

Jose Tinajero, PharmD, BCOP, discusses the role of the pharmacist in treatment planning and management in chronic myeloid leukemia.

The NCCN has released their updated Clinical Practice Guidelines in Oncology for NSCLC.

UGN-103 produced a 77.8% 3-month CR rate in patients with low-grade, intermediate-risk NMIBC.

Justin Taylor, MD, discusses findings from a study that evaluated the ability of ChatGPT to offer specific information in hematologic malignancies.

Oncology Fellows reports recent hematology/oncology fellows grant and award winners and looks ahead to upcoming grants.

Daniel P. Petrylak, MD, discusses key data in MIBC presented during the 2025 ESMO Congress and previews the 19th Annual New York GU Cancers Congress.

Primo Nery Lara, Jr, MD, and Suneel Kamath, MD, discuss the effects of federal cuts to cancer research despite public support for funding this research.

Harry P. Erba, MD, PhD; and Jayastu Senapati, MBBS, discuss the effects of drug shortages in hematologic oncology and how to adapt practice when they arise.

Margaret Wheless, MD, discusses findings from a study of end-of-life outcomes and health care resource utilization in ICI-treated HCC.

Carma L. Bylund, PhD, discussed the findings from a pilot study of a fellowship-level program for clinical trial communication skills.

Selumetinib has received approval in the EU for the management of plexiform neurofibromas in adult patients with neurofibromatosis type 1.

Arya Mariam Roy, MD, MBBS, discusses a study of the research productivity of hematology/oncology fellows who are international medical graduates.

Three cycles of platinum-based chemotherapy yielded superior PROs vs 6 cycles in advanced urothelial cancer.

Atezolizumab plus bevacizumab displayed preliminary signs of a TTFS benefit vs TACE in intermediate-stage HCC.

The FDA granted orphan drug designation to HLX43 for thymic epithelial tumors

Camrelizumab plus famitinib led to superior PFS and OS outcomes vs chemotherapy in frontline recurrent/metastatic cervical cancer.